300750 CONTEMPORARY AMPEREX TECHNOLOGY CO

EQS-News: Rentschler Biopharma appoints Tobias Glueck as SVP Human Relations

EQS-News: Rentschler Biopharma SE / Key word(s): Personnel
Rentschler Biopharma appoints Tobias Glueck as SVP Human Relations

13.10.2022 / 10:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


Rentschler Biopharma appoints Tobias Glueck as
Senior Vice President Human Relations

Laupheim, Germany, October 13, 2022 – Rentschler Biopharma, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, today announced that Tobias Glueck has joined the Company as Senior Vice President Human Relations. He leads the global HR team and is responsible for developing and coordinating HR activities at all three sites: Laupheim, Germany; Milford, MA, USA and Stevenage, UK. Tobias Glueck brings more than 25 years of human resources experience and has worked as an executive in both the U.S. and Germany.

He joins Rentschler Biopharma from Novartis Germany GmbH, where he served as Managing Director People & Organization, covering the full HR scope of the Pharma Business Unit and led all cross-divisional HR activities in Germany. He drove new corporate culture initiatives, initiated pilot programs to improve employee experience and significantly increased the number of people moves across the organization with a strong focus on diverse and international talents. Prior to that, Tobias Glueck was Vice President Human Resources at Cameron, a Schlumberger company, first in the Subsea Systems division and later in the Surface Systems division.  For this leading oilfield services company, he was based in the U.S. with HR responsibility for sites around the globe. In these positions, he successfully drove recruitment and retention activities, oversaw various transformation projects, and implemented and improved development programs. 

“I am excited to welcome Tobias Glueck to the Rentschler team. Tobias’ extensive international experience and expertise in diverse organizations align perfectly with our business strategy and focus on sustainable growth and long-term value creation. He knows the life sciences sector well, and his ability to navigate local cultures with a deep understanding of the industry will serve us well as our business expands,” said Dr. Frank Mathias, CEO of Rentschler Biopharma. “Our people are the heart of our success, and I look forward to Tobias driving our efforts to continually attract and retain highly qualified personnel.”

Tobias Glueck, Senior Vice President Human Relations, added: “It is my pleasure to be part of a team where we all share a clear vision of advancing medicine to save peoples‘ lives. I am impressed with the long legacy of Rentschler Biopharma as a family-owned business, while being an internationally active and globally successful leader. Strong collaboration paired with a positive corporate culture and employee experience were at the core of my career to date. In that spirit, I especially look forward to working with teams at each of our three sites to help address their specific people needs while we aim to grow the business and win new clients. Rentschler Biopharma has been constantly progressing, and we will continue to invest in our most valuable asset – our people.”

About Rentschler Biopharma SE

Rentschler Biopharma is a leading contract development and manufacturing organization (CDMO) focused exclusively on client projects. The company offers process development and manufacturing of biopharmaceuticals as well as related consulting activities, including project management and regulatory support. Rentschler Biopharma's high quality is proven by its long-standing experience and excellence as a solution partner for its clients. A high-level quality management system, a well-established operational excellence philosophy and advanced technologies ensure product quality and productivity at each development and manufacturing step. In order to offer best-in-class formulation development along the biopharmaceutical value chain, the company has entered into a strategic alliance with Leukocare AG. Rentschler Biopharma is a family-owned company with about 1,100 employees, headquartered in Laupheim, Germany, with a second site in Milford, MA, USA. In Stevenage, UK, Rentschler Biopharma has launched a company dedicated to cell and gene therapies, Rentschler ATMP Ltd.

For further information, please visit . Follow Rentschler Biopharma on and .

Contact:
Rentschler Biopharma SE

Dr. Cora Kaiser
Senior Director Corporate Communication
Phone: 4

Media inquiries:
MC Services AG

Eva Bauer
Phone:


U.S.
Laurie Doyle
Phone:

For a high-resolution image, please contact .



13.10.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at -news.com


1462375  13.10.2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1462375&application_name=news&site_id=research_pool
EN
13/10/2022

Underlying

300750CONTEMPORARY AMPEREX TECHNOLOGY CO

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CONTEMPORARY AMPEREX TECHNOLOGY CO

 PRESS RELEASE

EQS-News: vbw Pressemitteilung zum Koalitionsvertrag: Gute Grundlage

Emittent / Herausgeber: ibw – Informationszentrale der Bayerischen Wirtschaft e. V. / Schlagwort(e): Sonstiges/Sonstiges vbw Pressemitteilung zum Koalitionsvertrag: Gute Grundlage 10.04.2025 / 09:30 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. vbw zum Koalitionsvertrag: Gute Grundlage Brossardt: „Koalitionsvertrag schafft Planungssicherheit und setzt Wachstumsimpulse“  Bertram Brossardt, Hauptgeschäftsführer der vbw – Vereinigung der Bayerischen Wirtschaft e. V.: (München, 09.04.2025). Wir freuen uns, dass jetzt der Weg frei ist f...

 PRESS RELEASE

Aquis Stock Exchange - suspension of trading

Aquis Stock Exchange Aquis Stock Exchange - suspension of trading 10-Apr-2025 / 07:00 GMT/BST The issuer is solely responsible for the content of this announcement. The following securities are suspended from trading on the Aquis Growth Market from 08.00, 10 April 2025, at the request of the company: Richmond Hill Resources Plc Ordinary Shares Symbol: SHNJ ISIN: GB00BNTBWF32 The Regulation Department Aquis Stock Exchange Floor 2, 63 Queen Victoria Street, EC4N 4UA Tel: 0203 597 6361 Email:  Website:  Dissemination of a CORPORATE NEWS, transmitted by EQS Group.The i...

 PRESS RELEASE

EQS-News: CO2Coin one of the most successful crypto investments of the...

Issuer: Clima4Future Ltd. / Key word(s): Cryptocurrency / Blockchain/Market Launch CO2Coin one of the most successful crypto investments of the coming decades. 10.04.2025 / 04:55 CET/CEST The issuer is solely responsible for the content of this announcement.     CO2Coin is going through a phase of phenomenal growth. A year ago the price was just €1, today it is around 270 USDT - an increase in value that illustrates the enormous potential of this unique project. This development reflects the crypto community's growing interest in sustainable investments. Clima4Future Lt...

 PRESS RELEASE

EQS-News: CO2Coin eine der erfolgreichsten Krypto-Investitionen der ko...

Emittent / Herausgeber: Clima4Future Ltd. / Schlagwort(e): Kryptowährung / Blockchain/Markteinführung CO2Coin eine der erfolgreichsten Krypto-Investitionen der kommenden Jahrzehnte. 10.04.2025 / 04:55 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Der CO2Coin hat einen beeindruckenden Kursanstieg erlebt. Vor einem Jahr lag der Kurs noch bei 1 €, heute liegt er bei rund 270 USDT - eine Wertsteigerung, die das enorme Potenzial dieses einzigartigen Projekts verdeutlicht. Diese Entwicklung spiegelt das wachsende Interesse der Krypto-Com...

 PRESS RELEASE

EQS-News: Zimbabwe Government Delivers on Commitment: Compensation of ...

EQS-News: Zimbabwe Ministry of Finance, Economic Development and Investment Promotion / Key word(s): Miscellaneous Zimbabwe Government Delivers on Commitment: Compensation of Former Farm Owners under the Global Compensation Deed Commences 09.04.2025 / 20:20 CET/CEST The issuer is solely responsible for the content of this announcement. In line with the GCD agreement, the FFOs receive 1 per cent of their claim in cash, with the balance being paid through US$ denominated Treasury bonds with a 2 per cent coupon and maturities of 2 to 10 years HARARE, Zimbabwe, April 9, 2025...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch